Please assess the completion status of the following clinical trial:

Trial Title: Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed advanced solid tumors for which curative standard treatments are not available~  * Ten additional patients with extensive stage small cell lung cancer are accrued to the expanded cohort once a maximum tolerate dose (or a dose for further exploration) is determined~    * Must be chemotherapy naive~* Measurable or evaluable disease~  * Prior irradiated disease sites are considered measurable if there is clear disease progression following radiation therapy~* No uncontrolled brain or leptomeningeal metastases (including those requiring glucocorticoids)~PATIENT CHARACTERISTICS:~* Zubrod performance status 0-2~* Life expectancy \> 3 months~* Granulocyte count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Creatinine ≤ 1.3 mg/dL OR creatinine clearance \> 40 mL/min~* Serum bilirubin ≤ 1.5 mg/dL (regardless of liver involvement)~* SGOT ≤ 3 times upper limit of normal (ULN)~* INR ≤ 1.3 (≤ 3 if on anticoagulation)~* Fasting serum cholesterol ≤ 300 mg/dL\*~* Fasting triglycerides ≤ 2.5 times ULN\*~* No severe and/or uncontrolled medical co-morbidities or other conditions that could affect participation in the study including, but not limited to, the following:~  * Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤ 6 months prior to first study treatment~ * Serious uncontrolled cardiac arrhythmia~ * Severely impaired lung function~ * Active (acute or chronic) or uncontrolled infection~ * Non-malignant medical illness that is uncontrolled or that the control may be jeopardized by the study therapy~ * Liver disease (i.e., cirrhosis, chronic active hepatitis, chronic persistent hepatitis)~* No uncontrolled diabetes mellitus (i.e., fasting serum glucose \> 1.5 times ULN)~* No HIV seropositivity~* Not pregnant or nursing~* Fertile patients must use effective contraception~  * No oral, implantable, or injectable contraceptives~* No impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)~* No active, bleeding diathesis~* No known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipients~* Must be able to take and retain oral medication~* No peripheral neuropathy \> grade 1 as per NCI CTCAE vs. 3 NOTE: \*In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid-lowering medication.~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from prior therapy~* More than 3 weeks since prior and no concurrent investigational drugs~* At least 3 weeks since prior chemotherapy~* At least 2 weeks since prior major surgery or completion of radiotherapy~* No immunization with attenuated live vaccines within the past week or during study therapy~* No prior treatment with an mTOR inhibitor (e.g., sirolimus, temsirolimus, or everolimus)~* No chronic treatment with systemic steroids or other immunosuppressive agents~* No concurrent oral anti-vitamin K medication (except low dose coumadin)~* No concurrent medications interfering with everolimus~* No other concurrent anticancer agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase I Dose-Escalation (Type: EXPERIMENTAL): This is a phase I dose escalation study of RAD001 and carboplatin/etoposide. Patients will be accrued in a standard 3 + 3 design based on toxicities experienced during the first cycle. Ten additional chemotherapy naive extensive stage small cell lung cancer (ES-SCLC) patients will be accrued at the Maximum Tolerated Dose (MTD) for further toxicity and response assessment.

Based on this trial design, predict the completion outcome and termination type (if applicable).